0
₹0 0
Nextgen Biotech

Call us:

menu

Ruparib 300mg - Rucaparib Tablet

  • Home
  • Ruparib 300mg - Rucaparib Tablet

Ruparib 300mg - Rucaparib Tablet

Ruparib 300mg is an oral anti-cancer medication containing Rucaparib, a PARP inhibitor used to treat advanced ovarian and prostate cancers associated with BRCA mutations. It helps slow or stop the growth of cancer cells by interfering with their DNA repair process.

Select your size:

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Rucaparib
Brand Name: Ruparib
Packing: Bottle of 60 tablets
Strength: 300 mg
Manufacturer: [Specify manufacturer if known]
Form: Film-coated oral tablet
Category: Antineoplastic, PARP Inhibitor, Oral Chemotherapy
Product Intro:
Ruparib 300mg is a targeted chemotherapy drug that belongs to the class of Poly (ADP-ribose) Polymerase (PARP) inhibitors. It is specifically designed to treat ovarian, fallopian tube, peritoneal, and prostate cancers, especially in patients with BRCA gene mutations. It is taken orally and provides a personalized treatment approach to cancer.
Uses:
  1. Maintenance treatment of platinum-sensitive recurrent ovarian cancer
  2. BRCA-mutated ovarian cancer after two or more lines of chemotherapy
  3. Metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutation
  4. Investigational use in pancreatic and breast cancers with homologous recombination deficiencies
  5. Fallopian tube and primary peritoneal cancers
Storage Instructions:
  1. Store at room temperature (20°C to 25°C)
  2. Protect from moisture and direct sunlight
  3. Keep in original bottle with the desiccant
  4. Keep out of reach of children
How it Works (Mechanism of Action):
Ruparib is a PARP enzyme inhibitor. PARP enzymes help repair damaged DNA in cells. In BRCA-mutated cancer cells, which already have a deficient DNA repair system, Ruparib blocks the PARP pathway, leading to accumulation of DNA damage and ultimately cell death. This makes it effective in selectively killing cancer cells while sparing most normal cells.
Side Effects:
Common Side Effects:
  1. Nausea and vomiting
  2. Fatigue or tiredness
  3. Constipation or diarrhea
  4. Decreased appetite
  5. Changes in taste
  6. Anemia
Severe Side Effects:
  1. Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
  2. Bone marrow suppression
  3. Severe liver enzyme elevation
  4. Acute renal impairment
  5. Hypersensitivity reactions
Dosage (Typical Recommended Dose):
  1. 300 mg taken orally twice daily (total daily dose: 600 mg)
  2. Should be continued until disease progression or unacceptable toxicity
  3. Dosage adjustments may be required in case of adverse reactions
Method of Administration:
  1. Tablets should be swallowed whole, not crushed or chewed
  2. Can be taken with or without food
  3. Should be taken at regular intervals – every 12 hours
  4. If vomiting occurs after dosing, do not take an extra dose; wait for the next scheduled dose
Precautions:
  1. Confirm BRCA mutation status before initiating therapy
  2. Use with caution in patients with hepatic or renal impairment
  3. Women should avoid pregnancy; effective contraception required
  4. Not recommended in pediatric patients
  5. Regular blood monitoring is necessary during treatment
Drug Interactions:
  1. Avoid use with strong CYP3A inhibitors or inducers (e.g., rifampin, ketoconazole)
  2. May interact with P-gp substrates
  3. No known interaction with food
  4. Should be reviewed with any ongoing chemotherapy or immunotherapy
Allergies:
  1. Not to be used in individuals with known hypersensitivity to Rucaparib
  2. Allergic reactions may include rash, itching, swelling, and difficulty breathing
Overdose Information:
  1. In case of overdose, seek immediate medical attention
  2. Supportive care and symptomatic treatment recommended
  3. Monitor for signs of myelosuppression or organ dysfunction
Missed Dose Instructions:
  1. If a dose is missed, take it as soon as remembered
  2. If it is less than 6 hours before the next dose, skip the missed dose
  3. Do not double the dose to make up for a missed one
Additional Notes:
  1. Periodic CBC (Complete Blood Count) and liver/kidney function tests are necessary
  2. Patients should report any signs of infections, bleeding, or unusual fatigue
  3. Educate patients about contraception and fertility preservation options
  4. Inform patients that treatment is long-term and based on mutation-specific eligibility
View More

In The Same Category

Cart